Thomas A. McCourt net worth and biography

Thomas McCourt Biography and Net Worth

Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our chief executive officer and member of the board of directors since June 2021 and had served as president and interim chief executive officer from February 2021 to June 2021. Mr. McCourt had served as president from April 2019 to June 2021. Prior to April 2019, Mr. McCourt had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of ZELNORM™ for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for PRILOSEC® and NEXIUM®. Mr. McCourt serves on the board of directors, including on the audit and compensation committees, of Acceleron Pharma Inc. and has a degree in pharmacy from the University of Wisconsin.

What is Thomas A. McCourt's net worth?

The estimated net worth of Thomas A. McCourt is at least $7.85 million as of August 1st, 2022. Mr. McCourt owns 757,785 shares of Ironwood Pharmaceuticals stock worth more than $7,850,653 as of October 1st. This net worth evaluation does not reflect any other investments that Mr. McCourt may own. Additionally, Mr. McCourt receives a salary of $1,570,000.00 as CEO at Ironwood Pharmaceuticals. Learn More about Thomas A. McCourt's net worth.

How old is Thomas A. McCourt?

Mr. McCourt is currently 65 years old. There are 6 older executives and no younger executives at Ironwood Pharmaceuticals. Learn More on Thomas A. McCourt's age.

What is Thomas A. McCourt's salary?

As the CEO of Ironwood Pharmaceuticals, Inc., Mr. McCourt earned a total compensation package of $8,810,004.00 in 2021. Mr. McCourt earned a salary of $732,053.00, a bonus of $143,300.00, stock awards of $7,236,498.00, non-equity compensation of $680,063.00, and other compensation of $18,090.00. Learn More on Thomas A. McCourt's salary.

How do I contact Thomas A. McCourt?

The corporate mailing address for Mr. McCourt and other Ironwood Pharmaceuticals executives is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. Ironwood Pharmaceuticals can also be reached via phone at (617) 621-7722 and via email at [email protected] Learn More on Thomas A. McCourt's contact information.

Has Thomas A. McCourt been buying or selling shares of Ironwood Pharmaceuticals?

Thomas A. McCourt has not been actively trading shares of Ironwood Pharmaceuticals during the last quarter. Most recently, Thomas A. Mccourt sold 23,229 shares of the business's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $11.35, for a transaction totalling $263,649.15. Following the completion of the sale, the chief executive officer now directly owns 757,785 shares of the company's stock, valued at $8,600,859.75. Learn More on Thomas A. McCourt's trading history.

Who are Ironwood Pharmaceuticals' active insiders?

Ironwood Pharmaceuticals' insider roster includes Mark Currie (Director), Alexander Denner (Director), Thomas McCourt (CEO), Julie McHugh (Director), Jason Rickard (COO), Michael Shetzline (CMO), and Ronald Silver (Insider). Learn More on Ironwood Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ironwood Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 15 times. They sold a total of 536,963 shares worth more than $6,291,219.27. The most recent insider tranaction occured on August, 11th when Director Mark G Currie sold 70,000 shares worth more than $824,600.00. Insiders at Ironwood Pharmaceuticals own 13.1 % of the company. Learn More about insider trades at Ironwood Pharmaceuticals.

Information on this page was last updated on 8/11/2022.

Thomas A. McCourt Insider Trading History at Ironwood Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2022Sell23,229$11.35$263,649.15757,785View SEC Filing Icon  
6/30/2022Sell19,959$11.58$231,125.22778,922View SEC Filing Icon  
5/23/2022Sell36,308$11.50$417,542.00798,881View SEC Filing Icon  
12/22/2021Sell46,327$11.41$528,591.07View SEC Filing Icon  
11/23/2021Sell52,644$11.58$609,617.52View SEC Filing Icon  
5/24/2021Sell1,716$12.25$21,021.00566,499View SEC Filing Icon  
1/24/2020Sell20,000$12.71$254,200.00View SEC Filing Icon  
8/30/2019Sell220,000$9.24$2,032,800.00View SEC Filing Icon  
7/6/2018Sell30,000$20.00$600,000.0030,000View SEC Filing Icon  
5/15/2017Sell30,000$18.20$546,000.0030,000View SEC Filing Icon  
3/11/2013Sell40,000$17.00$680,000.00View SEC Filing Icon  
See Full Table

Thomas A. McCourt Buying and Selling Activity at Ironwood Pharmaceuticals

This chart shows Thomas A Mccourt's buying and selling at Ironwood Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ironwood Pharmaceuticals Company Overview

Ironwood Pharmaceuticals logo
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $10.36
Low: $10.34
High: $10.62

50 Day Range

MA: $11.19
Low: $10.14
High: $12.38

2 Week Range

Now: $10.36
Low: $10.01
High: $14.21

Volume

1,824,408 shs

Average Volume

2,764,567 shs

Market Capitalization

$1.59 billion

P/E Ratio

10.26

Dividend Yield

N/A

Beta

1.04